InvestSMART

ImpediMed Limited (ASX: IPD) - Announcements

Current share price for IPD : $0.004 0.001 (11.11%)+

ASX company news and announcements for ImpediMed Limited (IPD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ImpediMed Limited (IPD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ImpediMed Limited (IPD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ImpediMed Limited (IPD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 ImpediMed Releases Heart Failure and Renal Disease Software 15 Apr 2020 8:22AM $0.035 $0.004 fallen by 88.57%
$15 Settlement of Institutional Entitlement Offer 9 Apr 2020 6:19PM $0.035 $0.004 fallen by 88.57%
$15 Entitlement Offer - Notification to Ineligible Shareholders 9 Apr 2020 5:07PM $0.035 $0.004 fallen by 88.57%
$15 Dispatch of Prospectus and Entitlement & Acceptance Form 9 Apr 2020 5:01PM $0.035 $0.004 fallen by 88.57%
$15 ImpediMed Quarterly Results and Investor Conference Call 9 Apr 2020 11:42AM $0.035 $0.004 fallen by 88.57%
$15 Appendix 2A 8 Apr 2020 5:57PM $0.035 $0.004 fallen by 88.57%
$15 Issue of Shares 8 Apr 2020 5:57PM $0.035 $0.004 fallen by 88.57%
$15 Appendix 3G 8 Apr 2020 5:55PM $0.035 $0.004 fallen by 88.57%
$15 Successful Completion of $10m Institutional Portion of Offer 3 Apr 2020 9:53AM $0.040 $0.004 fallen by 90%
$15 Prospectus 2 Apr 2020 12:35PM $0.040 $0.004 fallen by 90%
$15 A$24.9million Non-Renounceable Accelerated Entitlement Offer 2 Apr 2020 12:35PM $0.040 $0.004 fallen by 90%
$15 Proposed issue of Securities - IPD 2 Apr 2020 12:03PM $0.040 $0.004 fallen by 90%
$15 ImpediMed Secures Order from Large US Oncology Care Network 31 Mar 2020 11:02AM $0.040 $0.004 fallen by 90%
$15 Trading Halt 30 Mar 2020 9:55AM $0.040 $0.004 fallen by 90%
$15 New National Purchasing Agreement for Lymphoedema Prevention 23 Mar 2020 8:36AM $0.048 $0.004 fallen by 91.67%
$15 Baylor Scott & White Expands SOZO Use with New iOS Software 20 Mar 2020 11:38AM $0.040 $0.004 fallen by 90%
$15 Executive Management Changes 20 Mar 2020 8:34AM $0.043 $0.004 fallen by 90.70%
$15 Final Director's Interest Notice 13 Mar 2020 12:13PM $0.061 $0.004 fallen by 93.44%
$15 Director Retirement 13 Mar 2020 12:12PM $0.061 $0.004 fallen by 93.44%
$15 Appendix 3G 21 Feb 2020 2:07PM $0.105 $0.004 fallen by 96.19%
$15 Appendix 4D and Interim Financial Report (Signed) 20 Feb 2020 10:21AM $0.110 $0.004 fallen by 96.36%
$15 Appendix 4D and Interim Financial Report 20 Feb 2020 9:30AM $0.105 $0.004 fallen by 96.19%
$15 Change in substantial holding 12 Feb 2020 4:17PM $0.115 $0.004 fallen by 96.52%
$15 Ceasing to be a substantial holder 11 Feb 2020 1:43PM $0.120 $0.004 fallen by 96.67%
$15 NCCN Guidelines for Breast Cancer Updated for Lymphoedema 10 Feb 2020 8:24AM $0.112 $0.004 fallen by 96.43%

676 - 700 of 1217 results

Page 28 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.